
Figure 1: Derivation of development (left panel) and validation (right panel) cohorts.

ONTARGET n=25,620



ORIGIN n=12,537

With Ramipril Global Endpoint Trial; ORIGIN, Outcome Reduction with Initial Glargine Intervention; UACR, urinary albumin-creatinine ratio.